Immunotherapy Drug Helping Lung Cancer Patients

Also read :Warming Planet Ups Risk of Deadly Tick-Borne Fever

The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.

Also read :Homeless Shelters Grapple With COVID Safety as Cold Creeps In

Also read :Annual Report Highlights Dangerous Toys

from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/article_thumbnails/blog_posts/cancer/metastatic_lung_cancer_blog/1800x1200_metastatic_lung_cancer_blog.jpg https://ift.tt/2GoGlJ9

Also read :Is the Pandemic Harming Kids' Mental Health?

via IFTTT